Curated News
By: NewsRamp Editorial Staff
April 28, 2025
Calidi Biotherapeutics Selects IL15 Superagonist for Antitumor Virotherapy Platform
TLDR
- Calidi Biotherapeutics selects IL15 superagonist as first therapeutic payload for RTNova platform, enhancing immune response and tumor elimination.
- Preclinical data at AACR Annual Meeting demonstrates Calidi's engineered vaccinia virus can deliver IL15 superagonist directly into tumor microenvironment for systemic antitumor virotherapy.
- Calidi's RTNova platform aims to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies, potentially improving patient outcomes and quality of life.
- Calidi Biotherapeutics' innovative approach in utilizing IL15 superagonist for antitumor virotherapy showcases promising advancements in cancer treatment and immune response modulation.
Impact - Why it Matters
This news highlights a groundbreaking approach in cancer treatment with the potential to significantly enhance immune response and eliminate tumors while minimizing side effects. It showcases the innovative technology developed by Calidi Biotherapeutics in the fight against metastatic cancers, offering hope for improved efficacy and patient safety in cancer therapy.
Summary
Calidi Biotherapeutics announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while minimizing systemic toxicity.
The RTNova platform aims to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies. Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer using stem cell-based platforms capable of carrying oncolytic viruses for multiple oncology indications.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics Selects IL15 Superagonist for Antitumor Virotherapy Platform
